Broncus Holding 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Hong Xu

최고 경영자

US$169.0k

총 보상

CEO 급여 비율	96.4%
CEO 임기	1.2yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.3yrs

최근 관리 업데이트

Recent updates

An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued

Dec 06

Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers

Sep 04

Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation

Jun 21

CEO 보상 분석

Hong Xu 의 보수는 Broncus Holding 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$21m
Mar 31 2024	n/a	n/a	-US$25m
Dec 31 2023	US$169k	US$163k	-US$28m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$214k	US$208k	-US$28m
Sep 30 2022	n/a	n/a	-US$119m
Jun 30 2022	n/a	n/a	-US$209m
Mar 31 2022	n/a	n/a	-US$222m
Dec 31 2021	US$210k	US$170k	-US$236m

보상 대 시장: Hong 의 총 보상 ($USD 169.00K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 233.11K ).

보상과 수익: Hong 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Hong Xu (37 yo)

1.2yrs

테뉴어

US$169,000

보상

Mr. Hong Xu is the Chairman of the Board at Broncus Holding Corporation since April 19, 2024 and is an Executive Director since May 6, 2021 and is also its Chief Executive Officer since September 1, 2023....

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hong Xu	Chairman of the Board & CEO	3.5yrs	US$169.00k	데이터 없음
Ao Zhang	Non-Executive Director	3.6yrs	데이터 없음	데이터 없음
Pok Man Kam	Independent Non-Executive Director	3.2yrs	US$51.00k	데이터 없음
Yee Sin Wong	Independent Non-Executive Director	2.3yrs	US$51.00k	데이터 없음
Yiqian Huang	Independent Non-Executive Director	2.3yrs	데이터 없음	데이터 없음
David Lim	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음
Yanhong Kuang	Non-Executive Director	less than a year	데이터 없음	0.0027% HK$ 6.5k

2.3yrs

평균 재임 기간

48.5yo

평균 연령

경험이 풍부한 이사회: 2216 의 이사회는 경험(평균 재직 기간 2.3 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Broncus Holding 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Broncus Holding Corporation Announces Management Changes

Broncus Holding Corporation Announces Changes to Its Board

Broncus Holding Corporation, Annual General Meeting, May 20, 2024

Broncus Holding Corporation Announces Resignation of Zhenjun Zi as Non-Executive Director

Broncus Holding Corporation Announces Chief Executive Officer Changes, Effective on September 1, 2023

Broncus Holding Corporation Announces Re-Designation of Guowei Zhan from an Executive Director to Non-Executive Director, Effective September 1, 2023

Recent updates

First half 2024 earnings released: US$0.016 loss per share (vs US$0.03 loss in 1H 2023)

Broncus Holding Corporation to Report Q2, 2024 Results on Aug 29, 2024

Broncus Holding Corporation Announces Management Changes

Broncus Holding Corporation Announces Changes to Its Board

Full year 2023 earnings: EPS and revenues miss analyst expectations

Broncus Holding Corporation, Annual General Meeting, May 20, 2024

We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully

Broncus Holding Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

Broncus Holding Corporation Announces Resignation of Zhenjun Zi as Non-Executive Director

Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans

Broncus Holding Corporation (SEHK:2216) entered into share purchase agreement to acquire Fibernova Holding Corporation from from Zhao and others for $2.7 million.

First half 2023 earnings released: US$0.03 loss per share (vs US$0.033 loss in 1H 2022)

Broncus Holding Corporation Announces Chief Executive Officer Changes, Effective on September 1, 2023

Broncus Holding Corporation Announces Re-Designation of Guowei Zhan from an Executive Director to Non-Executive Director, Effective September 1, 2023

Broncus Holding Corporation to Report First Half, 2023 Results on Aug 29, 2023

Broncus Holding Corporation Completes the First Case of Registered Clinical Trials of Its Targeted Lung Denervation Radiofrequency Ablation System

Will Broncus Holding (HKG:2216) Spend Its Cash Wisely?

Consensus estimates of losses per share improve by 48%

Consensus revenue estimates fall by 36%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Companies Like Broncus Holding (HKG:2216) Are In A Position To Invest In Growth

An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued

Less than half of directors are independent

Broncus Holding Corporation Announces Zhejiang Medical Products Administration Approves Disposable Nebulizing Micro-Catheter for Endoscope for Marketing in China

Consensus forecasts updated

Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers

First half 2022 earnings released: US$0.03 loss per share (vs US$0.19 loss in 1H 2021)

Broncus Holding Corporation Announces Board and Executive Changes

Broncus Holding Corporation to Report First Half, 2022 Results on Aug 30, 2022

Consensus EPS estimates fall by 16%

Broncus Holding Corporation Completes Surgeries on the First Group of Patients Using Its InterVapor, the Thermal Vapor Treatment System, After Approved for Marketing in China

Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Broncus Holding Corporation, Annual General Meeting, May 13, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

Broncus Holding Corporation Announces Resignation of Wen Hao Wang as Chief Financial Officer

Non Executive Director recently bought HK$390k worth of stock

Broncus Holding Corporation announces Enrollment for Registered Clinical Trials Successfully Completed for RF-II in China

Broncus Holding Corporation has completed an IPO in the amount of HKD 1.670939 billion.

Less than half of directors are independent

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령